Synlogic, Inc. (NASDAQ:SYBX) rose following new product news.
Earlier in the month Synlogic said it initiated Phase 1 study of the SYNB8802 for the treatment of Enteric Hyperoxaluria.
Said CEO Aoife Brennan, “We are gaining momentum across our three clinical stage programs as we head into the end of the year.
“We are ahead of schedule in moving SYNB8802—our investigational Synthetic Biotic for the treatment of Enteric Hyperoxaluria—into the clinic and initiated the Phase 2 SynPheny-1 study in PKU patients.
“On the corporate side, we have strengthened our leadership team with the addition of Dr. David Hava as Chief Scientific Officer. With a strong cash runway, we have the resources to execute on our key clinical milestones over the next 12 months, extending our lead as the premier platform for engineered Synthetic Biotic medicines.”
“We are thrilled with the recent progress moving two programs forward in the clinic. Initiation of the Phase 2 SynPheny-1 study of SYNB1618 puts us on track to see data in PKU patients around the middle of next year,” said Richard Riese , M.D., Synlogic’s Chief Medical Officer.
Initiation of a Phase 2 clinical trial to evaluate SYNB1618 in patients with P henylketonuria (PKU) , with data expected in the middle of 2021 . SYNB1618 is an orally administered Synthetic Biotic medicine being developed as a potential treatment for PKU.
Based on feedback from patients and caregivers Synlogic believes both current and emerging treatment options will continue to leave too many patients behind.
Shares acquired 9.5 cents, or 3.9%, to $2.55.